ArticleAsian Pacific journal of cancer prevention : APJCP2025
Prognosis of Brain Metastases (BM) Patient Received Whole Brain Radiation Therapy (WBRT) alone or in combination with Surgery at Dharmais National Cancer Center, Indonesia.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Safety and efficacy of delivering systemic treatments concomitantly with whole-brain radiotherapy: a prospective, observational, single-institution study.Exploration of targeted anti-tumor therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWBRT and surgery are commonly used to improve the overall survival of BM patients. The study aims to evaluate the overall survival of patients treated with WBRT in combination with surgery or alone.
methodsThis study is a cohort retrospective of 148 BM patients from January 1st, 2021, to December 31st, 2022, and our follow-up on their overall survival up to July 1st, 2023. We collected data on treatments received either in combination with WBRT and surgery or alone. Information for age, sex, primary tumor types, and sites of metastases were collected. Median survival time, Kaplan-Meier curves, and its' log-rank statistics were presented, including the results of Cox regression analysis.
resultsThe overall median survival of this sample was 4.3 months. Patients receiving WBRT exhibit higher survival rates than non-WBRT (median survival rates are 6.9 vs 1.5 months) but not surgery (4.0 vs 4.4 months). The primary tumors (breast, lung, and others) have no difference in the median survival rates. The survival rate using Kaplan-Meier showed a significant difference between patients with WBRT vs non-WBRT (log-rank p=0.0) but not for surgery. A Cox regression shows hazard ratio (HR) for patients receiving WBRT=0.34 [95% CI: 0.19-0.62; P<0.001] and when it is adjusted for surgery and other variables it exhibits only a small change.
conclusionBM patients who received WBRT had better survival than non-WBRT patients, which could reduce HR, but surgery was not statistically significant. All BM patients should receive WBRT regardless of surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.